180 related articles for article (PubMed ID: 32411764)
1. The neutrophil-to-lymphocyte ratio is a predictive factor for the survival of patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Wang C; Wang M; Zhang X; Zhao S; Hu J; Han G; Liu L
Ann Transl Med; 2020 Apr; 8(8):541. PubMed ID: 32411764
[TBL] [Abstract][Full Text] [Related]
2. Dynamic Changes in the Neutrophil-to-Lymphocyte Ratio Predict the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Wang H; Lin C; Fan W; Zhang J; Zhang Y; Yao W; Li J
Cancer Manag Res; 2020; 12():3433-3444. PubMed ID: 32523374
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib.
Zhang L; Yan ZP; Hou ZH; Huang P; Yang MJ; Zhang S; Zhang S; Zhang SH; Zhu XL; Ni CF; Li Q
Front Mol Biosci; 2021; 8():624366. PubMed ID: 34124139
[No Abstract] [Full Text] [Related]
4. Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization.
Zhou D; Liang J; Xu LI; He F; Zhou Z; Zhang Y; Chen M
Oncol Lett; 2016 May; 11(5):2987-2994. PubMed ID: 27123051
[TBL] [Abstract][Full Text] [Related]
5. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
He CB; Lin XJ
PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
[TBL] [Abstract][Full Text] [Related]
6. Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined With Radiofrequency Ablation.
Yang XG; Huang YC; Wang CH; Sun YY; Huang Z; Xu GH
Cancer Invest; 2022 Jul; 40(6):494-504. PubMed ID: 35404178
[TBL] [Abstract][Full Text] [Related]
7. Diabetes mellitus and the neutrophil to lymphocyte ratio predict overall survival in non-viral hepatocellular carcinoma treated with transarterial chemoembolization.
Zhang J; Gong F; Li L; Zhao M; Song J
Oncol Lett; 2014 May; 7(5):1704-1710. PubMed ID: 24765205
[TBL] [Abstract][Full Text] [Related]
8. A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma.
Liu J; Zhang W; Niu R; Li Y; Zhou X; Han X
Saudi Med J; 2020 Apr; 41(4):376-382. PubMed ID: 32291424
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Rebonato A; Graziosi L; Maiettini D; Marino E; De Angelis V; Brunese L; Mosca S; Metro G; Rossi M; Orgera G; Scialpi M; Donini A
Gastroenterol Res Pract; 2017; 2017():4164130. PubMed ID: 28894464
[TBL] [Abstract][Full Text] [Related]
10. The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy.
He C; Zhang Y; Cai Z; Lin X
Cancer Manag Res; 2019; 11():1391-1400. PubMed ID: 30863150
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil-to-Lymphocyte Ratio as a Biomarker Predicting Overall Survival after Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma.
Chu HH; Kim JH; Shim JH; Gwon DI; Ko HK; Shin JH; Ko GY; Yoon HK; Kim N
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204125
[TBL] [Abstract][Full Text] [Related]
12. Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Chon YE; Park H; Hyun HK; Ha Y; Kim MN; Kim BK; Lee JH; Kim SU; Kim DY; Ahn SH; Hwang SG; Han KH; Rim KS; Park JY
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30974843
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization.
Fan W; Zhang Y; Wang Y; Yao X; Yang J; Li J
PLoS One; 2015; 10(3):e0119312. PubMed ID: 25742141
[TBL] [Abstract][Full Text] [Related]
14. Combination of psoas muscle mass index and neutrophil/lymphocyte ratio as a prognostic predictor for patients undergoing nonsurgical hepatocellular carcinoma therapy.
Sugama Y; Miyanishi K; Osuga T; Tanaka S; Hamaguchi K; Ito R; Sakamoto H; Kubo T; Ohnuma H; Murase K; Takada K; Kobune M; Kato J
JGH Open; 2021 Dec; 5(12):1335-1343. PubMed ID: 34950776
[TBL] [Abstract][Full Text] [Related]
15. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma.
Pinato DJ; Sharma R
Transl Res; 2012 Aug; 160(2):146-52. PubMed ID: 22677364
[TBL] [Abstract][Full Text] [Related]
16. Systemic inflammatory response predicts poor prognoses in Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma with transarterial chemoembolization: a prospective study.
Huang Z; Lu W; Yu N; Yang G; Xu H; Liu H
Transl Cancer Res; 2019 Nov; 8(7):2552-2563. PubMed ID: 35117012
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory Scores: Comparison and Utility in HCC Patients Undergoing Transarterial Chemoembolization in a North American Cohort.
Young S; Cam I; Gencturk M; Rubin N; D'souza D; Flanagan S; Golzarian J; Sanghvi T
J Hepatocell Carcinoma; 2021; 8():1513-1524. PubMed ID: 34881208
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization.
McNally ME; Martinez A; Khabiri H; Guy G; Michaels AJ; Hanje J; Kirkpatrick R; Bloomston M; Schmidt CR
Ann Surg Oncol; 2013 Mar; 20(3):923-8. PubMed ID: 22965570
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
He CB; Lao XM; Lin XJ
Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
